hmm I take your point but to be fair pavors H1 2014 was half best revenue yet, and it is bound to be lumpy while so reliant on clinical trials. This isn't an explosive growth story it is a slow build story by with HepaFat on the verge of contributing it isn't unreasonable that revenue growth will increase.
hmm I take your point but to be fair pavors H1 2014 was half...
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RHT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $24.57M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 200000 | 5.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.6¢ | 116743 | 2 |
View Market Depth
| Last trade - 16.12pm 12/07/2024 (20 minute delay) ? |
| RHT (ASX) Chart |
Day chart unavailable